Carbyne invests in ITM
Carbyne Equity Partners invests in ITM – Isotope Technologies Munich SE together with Temasek, BlackRock, QIA, Nextech and ATHOS.
ITM is a leading radiopharmaceutical company with an advanced proprietary pipeline for cancer treatment and has established itself as the major radioisotope supplier globally. Together with Temasek, Black Rock, QIA, Nextech and Athos, this transaction is one of the largest private investment rounds in European biotech to-date. Please find the following download link to ITM´s press release.